Stayble Therapeutics AB (SE:STABL)
:STABL
Want to see SE:STABL full AI Analyst Report?
Top Page
Stayble Therapeutics AB
(STABL)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr0.04
▼(-82.08% Downside)
Action:ReiteratedDate:04/29/26
The score is held down primarily by weak financial fundamentals (no revenue, ongoing losses and cash burn, shrinking equity) and a strong technical downtrend (price below key moving averages with negative momentum). Improving loss and cash-burn trends and low debt provide some support, but valuation signals are limited given negative earnings and no dividend.
Positive Factors
Low leverage / minimal debt
A near-zero debt load is a durable strength for a pre-revenue biotech: it reduces fixed financing obligations, preserves strategic flexibility for funding R&D or partnering, and lowers bankruptcy risk, allowing management to prioritize clinical milestones over debt servicing.
Negative Factors
No revenue (pre-commercial)
Absence of product revenue is a fundamental long-term risk: the business remains fully dependent on external capital or partnerships to fund trials and operations, creating execution and financing risk until regulatory approval and commercial launch occur.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / minimal debt
A near-zero debt load is a durable strength for a pre-revenue biotech: it reduces fixed financing obligations, preserves strategic flexibility for funding R&D or partnering, and lowers bankruptcy risk, allowing management to prioritize clinical milestones over debt servicing.
Read all positive factors
Stayble Therapeutics AB (STABL) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr2.52M
Dividend YieldN/A
Average Volume (3M)378.51K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue GrowthN/A
EPS Growth63.63%
CountrySE
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding64,359,795
10 Day Avg. Volume398,578
30 Day Avg. Volume378,512
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.92
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Stayble Therapeutics AB Business Overview & Revenue Model
Company Description
Stayble Therapeutics AB (STABL) is a clinical-stage pharmaceutical company based in Sweden that focuses on developing innovative treatments for degenerative disc disease and other musculoskeletal disorders. The company is primarily engaged in the ...
How the Company Makes Money
null...
Stayble Therapeutics AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -148.21K | 0.00 | 0.00 | 0.00 |
| EBITDA | -6.90M | -12.22M | 309.41K | -24.50M | -12.03M |
| Net Income | -6.93M | -12.42M | -23.74M | -24.53M | -12.04M |
Balance Sheet | |||||
| Total Assets | 8.62M | 9.26M | 21.70M | 19.15M | 43.64M |
| Cash, Cash Equivalents and Short-Term Investments | 2.45M | 2.19M | 14.08M | 12.85M | 37.47M |
| Total Debt | 0.00 | 850.00K | 850.00K | 850.00K | 850.00K |
| Total Liabilities | 1.70M | 2.38M | 5.19M | 3.87M | 3.83M |
| Stockholders Equity | 6.92M | 6.87M | 16.51M | 15.28M | 39.81M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -14.67M | -23.54M | -24.89M | -9.63M |
| Operating Cash Flow | -6.72M | -14.67M | -23.54M | -24.89M | -9.63M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 1.00K | -1.00K |
| Financing Cash Flow | 6.98M | 2.78M | 24.96M | 1.00K | 36.15M |
Stayble Therapeutics AB Technical Analysis
Negative
0.24
Price Trends
0.18
Negative
0.20
Negative
0.26
Negative
Market Momentum
-0.01
Positive
32.46
Neutral
17.61
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STABL, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.18, and below the 200-day MA of 0.26, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 32.46 is Neutral, neither overbought nor oversold. The STOCH value of 17.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:STABL.
Stayble Therapeutics AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:STABL
Stayble Therapeutics AB
0.04
-0.40
-91.14%
SE:LARK
CombiGene AB
2.19
-0.23
-9.47%
SE:FLUI
Fluicell AB
14.25
2.05
16.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.